Cannabis Safety & Efficacy
via Science & Technology
Cannabis has gained widespread attention in recent years, and has been used to treat or alleviate symptoms of various diseases and conditions. According to a report by imarc, the global medical cannabis market is expected to reach US $44 billion by 2024, supported by investments in clinical trials and R&D. However, as scientists continue to learn more about cannabinoids and their medicinal effects, there remains no standardized assessment of efficacy for cannabis in clinical diagnostics. Furthermore, the vast variety of pure/hybrid cannabis plants and their growing conditions adds to the complexity of attempts to create such a standardized assessment.
JUNOKANA is reverse-engineering the standardization process by measuring and defining metabolic response due to cannabis use or treatment.
Metabolomics...
-
provides a picture of health
-
can aid in the diagnosis of disease
-
can measure the efficacy of cannabis-based treatment
-
can assess the body's inner response to cannabis use/treatment
-
can characterize each person's biochemical response to different varieties of cannabis (enable personalized medical cannabis treatment)
-
can lead the future of cannabis clinical application and testing to enable better patient care
Specifically designed to guide cannabis-based materials, products, and services into compliance with government regulations for conducting scientific research, including clinical studies performed on behalf of customer companies.
-
Cannabis-based materials and products (Producer)
-
Cannabis-based materials and products that are subject to FDA and other government agency compliance regulation
-
-
Cannabis pharmacologists and dispensaries (Distributor)
-
JUNOKANA Cannabis Consumer Kit helps pharmacologists make safe and medically sound recommendations for cannabis use
-
Safety and Efficacy Testing for the Entire Cannabis Market*
-
cannabis patients and consumers
-
dispensaries and product distributors
-
farms, growers, and product manufacturers
*Disclaimer: JUNOKANA Kit provides information about the state of metabolic pathways in a patient treated with medical cannabis products. It is not a diagnostic test and is not cleared by the US Food and Drug Administration.
What We Do
We provide metabolomics based tools and services that measure efficacy/safety of cannabis products, establishing a framework of standardization missing in today's market.
Who We Are
Stephan Kang (CEO) and Tim Garrett, Ph.D. (CSO) bring the best of bioinformatics and scientific innovation to the core of JUNOKANA's data driven technology.
Impact
A first-of-its-kind solution for cannabis efficacy testing in humans, JUNOKANA is assisting customers seeking FDA approval. We aim to be the gold standard in cannabis efficacy & safety testing.
